Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emily M Hinchcliff

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Gynecologic Oncology|September 11, 2016
Trends in the use of neoadjuvant chemotherapy for advanced ovarian cancer in the United StatesAlexander Melamed, Emily M Hinchcliff, Joel T Clemmer, et al.
Annals of Surgical Oncology|May 10, 2015
Same-Day Discharge After Laparoscopic Hysterectomy for Endometrial CancerAlexander Melamed, Jennifer L Katz Eriksen, Emily M Hinchcliff, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 24, 2014
Clinical outcomes of women with recurrent or persistent uterine leiomyosarcomaJose Alejandro Rauh-Hain, Emily M Hinchcliff, Titilope Oduyebo, et al.
Iscience|May 10, 2024
Phase 1b study of batiraxcept in combination with durvalumab in patients with platinum-resistant ovarian cancerAnne Knisely, Emily M Hinchcliff, Elisabeth Gardiner, et al.
Gynecologic Oncology|September 15, 2018
A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practiceAmir Jazaeri, Robert L Coleman, Anil K Sood, et al.
Cancer|November 27, 2023
Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancerEmily M Hinchcliff, Anne Knisely, Naomi Adjei, et al.
The New England Journal of Medicine|March 27, 2023
Pembrolizumab plus Chemotherapy in Advanced Endometrial CancerRamez N Eskander, Michael W Sill, Lindsey Beffa, et al.
Nature Medicine|March 5, 2025
Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trialRamez N Eskander, Michael W Sill, Lindsey Beffa, et al.
Nature|July 3, 2025
PPP2R1A mutations portend improved survival after cancer immunotherapyYibo Dai, Anne Knisely, Mitsutake Yano, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Gynecologic Oncology|September 11, 2016
Trends in the use of neoadjuvant chemotherapy for advanced ovarian cancer in the United StatesAlexander Melamed, Emily M Hinchcliff, Joel T Clemmer, et al.
Annals of Surgical Oncology|May 10, 2015
Same-Day Discharge After Laparoscopic Hysterectomy for Endometrial CancerAlexander Melamed, Jennifer L Katz Eriksen, Emily M Hinchcliff, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 24, 2014
Clinical outcomes of women with recurrent or persistent uterine leiomyosarcomaJose Alejandro Rauh-Hain, Emily M Hinchcliff, Titilope Oduyebo, et al.
Iscience|May 10, 2024
Phase 1b study of batiraxcept in combination with durvalumab in patients with platinum-resistant ovarian cancerAnne Knisely, Emily M Hinchcliff, Elisabeth Gardiner, et al.
Gynecologic Oncology|September 15, 2018
A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practiceAmir Jazaeri, Robert L Coleman, Anil K Sood, et al.
Cancer|November 27, 2023
Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancerEmily M Hinchcliff, Anne Knisely, Naomi Adjei, et al.
The New England Journal of Medicine|March 27, 2023
Pembrolizumab plus Chemotherapy in Advanced Endometrial CancerRamez N Eskander, Michael W Sill, Lindsey Beffa, et al.
Nature Medicine|March 5, 2025
Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trialRamez N Eskander, Michael W Sill, Lindsey Beffa, et al.
Nature|July 3, 2025
PPP2R1A mutations portend improved survival after cancer immunotherapyYibo Dai, Anne Knisely, Mitsutake Yano, et al.
Pageof 2